First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder	Recruiting	Phase 2	2026-09-15		NCT06730373

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Qilu Hospital of Shandong University	249

20 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Jining Medical College	Jining	China	5
Binzhou Medical University Hospital	Binzhou	China	10
Jinan Third People's Hospital	Jinan	China	2
Liaocheng People's Hospital	Liaocheng	China	16
Linyi Cancer Hospital	Linyi	China	22
Qilu Hospital of Shandong University(Qingdao)	Qingdao	China	2
Shandong Provincial Hospital Affiliated to Shandong First Medical University	Jinan	China	5
Shandong Provincial Third Hospital	Jinan	China	2
Shandong Univerisity Qilu Hospital	Jinan	China	1
Shengli Oilfield Central Hospital	Dongying	China	4
Taian City Central Hospital	Taian	China	2
Tengzhou Central People's Hospital	Tengzhou	China	2
The Affiliated Hospital of Qingdao University	Qingdao	China	48
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	125
The Second Affiliated Hospital of Shandong First Medical University	Taian	China	3
Weifang Hospital of Traditional Chinese Medicine	Weifang	China	3
Yantai Yuhuangding Hospital	Yantai	China	19
Yantaishan Hospital	Yantai	China	2
Zibo Central Hospital	Zibo	China	13
Zibo First People's Hospital	Zibo	China	2

Clinical trials